Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment - Full Text View

Sponsors and Collaborators:	University of Sao Paulo Fundação de Amparo à Pesquisa do Estado de São Paulo CNPq Novartis
Information provided by:	University of Sao Paulo
ClinicalTrials.gov Identifier:	NCT00466609

Purpose

This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for OCD. The investigators will compare the association of an SSRI (fluoxetine) with quetiapine, SSRI with clomipramine and SSRI with placebo for 12 weeks.

Condition	Intervention	Phase
Obsessive Compulsive Disorder	Drug: Association of clomipramine and fluoxetine Drug: Association of quetiapine and fluoxetine Drug: Association of placebo and fluoxetine	Phase IV

MedlinePlus related topics: Obsessive-Compulsive Disorder

Drug Information available for: Fluoxetine Quetiapine Quetiapine fumarate Fluoxetine hydrochloride Clomipramine Clomipramine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-Respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:

Rates of improvement after 12 weeks of treatment based on the difference of initial and final Yale Brown Obsessive Compulsive Scale (YBOCS) scores for obsessions and compulsions. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Improvement of quality of life (QOL) will be assessed through SF-36 administered on weeks 0 and 12; [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Improvement of social adaptation using the Social Adaptation Scale (SAS) (Weissman & Payket, 1974) administered on weeks 0 and 12; [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Tolerability of the proposed treatments through adverse events follow-up performed each visit (emphasis in serotonergic syndrome) [ Time Frame: weeks 0,1,2,3,4,8,12 ] [ Designated as safety issue: Yes ]
Score obtained with Beck depression inventory (BDI) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Score obtained with Beck´s anxiety inventory (BAI) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Clinical global impression measure of improvement [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Change from baseline EKG regarding QT interval [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
Fluoxetine dosage and Clomipramine dosage (when applies) [ Time Frame: weeks 2 and 12 ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	90
Study Start Date:	May 2007
Estimated Study Completion Date:	October 2009
Estimated Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Quetiapine plus fluoxetine	Drug: Association of quetiapine and fluoxetine Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
2: Experimental Clomipramine plus fluoxetine	Drug: Association of clomipramine and fluoxetine Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
3: Placebo Comparator Placebo plus fluoxetine	Drug: Association of placebo and fluoxetine Placebo plus fluoxetine at maximum dosage of 80mg per day

Detailed Description:

Arm 1: SSRI (Fluoxetine 40mg* once a day) + Clomipramine 75mg* once a day. Arm 2: SSRI (Fluoxetine 40mg* once a day) + Quetiapine 200mg* once a day. Arm 3: SSRI (Fluoxetine 80mg* once a day) + Placebo once a day.

* or maximum tolerated dose

We hypothesize that quetiapine and clomipramine will be effective augmentation strategies for resistant OCD patients in comparison to placebo

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

OCD diagnosis
YBOCS score ≥ 16 (for patients with both obsessions and compulsions) or ≥ 10 (for patients with only obsessions or compulsions)
Previously signed informed consent to participate in this clinical trial

Exclusion Criteria:

Patients with clinical or neurological diseases that may be worsen by the medications included in treatment protocol
Current substance dependence or abuse
Current psychotic symptoms
Current suicide risk
Current pregnancy or intention to get pregnant before the end of the treatment protocol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00466609

Contacts

Contact: Izabel Pimentel, Nurse	5511 30696972 ext 169	izabelpimentel@terra.com.br
Contact: Juliana Diniz, MD	5511 30696972 ext 170	juliana@protoc.com.br

Locations

Brazil, SP
Institute of Psychiatry	Recruiting
Sao Paulo, SP, Brazil, 05403-010

Sponsors and Collaborators

University of Sao Paulo

Fundação de Amparo à Pesquisa do Estado de São Paulo

CNPq

Novartis

Investigators

Principal Investigator:

Juliana B Diniz, MD

University of Sao Paulo Medical School

More Information

Main research group involved in this study This link exits the ClinicalTrials.gov site

Institutional site of main sponsor This link exits the ClinicalTrials.gov site

Responsible Party:	University of São Paulo ( Juliana Belo Diniz )
Study ID Numbers:	05/55628-8, 2005/55628-08
Study First Received:	April 26, 2007
Last Updated:	November 10, 2008
ClinicalTrials.gov Identifier:	NCT00466609
Health Authority:	Brazil: National Committee of Ethics in Research

Keywords provided by University of Sao Paulo:

clomipramine
quetiapine
fluoxetine

placebo
augmentation
obsessive compulsive disorder

Study placed in the following topic categories:

Fluoxetine
Quetiapine
Anxiety Disorders
Mental Disorders

Clomipramine
Serotonin
Obsessive-Compulsive Disorder

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antipsychotic Agents

Serotonin Uptake Inhibitors
Pharmacologic Actions
Antidepressive Agents, Tricyclic
Pathologic Processes
Serotonin Agents
Therapeutic Uses
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on January 15, 2009